Steward Partners Investment Advisory LLC Boosts Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Steward Partners Investment Advisory LLC raised its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 217.8% in the 4th quarter, Holdings Channel reports. The fund owned 14,565 shares of the company’s stock after acquiring an additional 9,982 shares during the quarter. Steward Partners Investment Advisory LLC’s holdings in Recursion Pharmaceuticals were worth $98,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Wedmont Private Capital raised its stake in shares of Recursion Pharmaceuticals by 10.6% during the 4th quarter. Wedmont Private Capital now owns 20,943 shares of the company’s stock worth $144,000 after buying an additional 2,000 shares in the last quarter. Green Alpha Advisors LLC raised its stake in shares of Recursion Pharmaceuticals by 3.6% during the 4th quarter. Green Alpha Advisors LLC now owns 67,145 shares of the company’s stock worth $454,000 after buying an additional 2,346 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Recursion Pharmaceuticals by 5.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 52,530 shares of the company’s stock worth $346,000 after buying an additional 2,667 shares in the last quarter. KBC Group NV raised its stake in shares of Recursion Pharmaceuticals by 79.9% during the 3rd quarter. KBC Group NV now owns 7,602 shares of the company’s stock worth $50,000 after buying an additional 3,377 shares in the last quarter. Finally, Decker Retirement Planning Inc. purchased a new position in shares of Recursion Pharmaceuticals during the 4th quarter worth approximately $26,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

RXRX has been the subject of a number of analyst reports. KeyCorp cut their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Leerink Partners cut their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a research note on Friday, February 28th. Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Finally, Cowen restated a “hold” rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, Recursion Pharmaceuticals presently has an average rating of “Hold” and an average price target of $8.25.

Recursion Pharmaceuticals Stock Performance

RXRX opened at $6.84 on Tuesday. The stock has a market cap of $2.75 billion, a P/E ratio of -4.47 and a beta of 0.85. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The stock’s 50 day simple moving average is $7.52 and its 200 day simple moving average is $7.01. Recursion Pharmaceuticals, Inc. has a 1-year low of $5.60 and a 1-year high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). The firm had revenue of $4.60 million during the quarter, compared to analyst estimates of $19.04 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business’s revenue was down 57.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.42) EPS. As a group, equities analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.